ContraVir Pharmaceuticals, Inc. (CTRV) Stock: Here’s The Scoop


The social space is buzzing about ContraVir Pharmaceuticals, Inc. (CTRV). So, you may be wondering what’s happening with the company. The number of possible catalysts for such a large amount of interest is pretty big. It might be caused by the return on investment that investors have seen from CTRV, the volume on the stock, or a number of other technical and fundamental factors. In this article, we’ll take a detailed look at the stock to find out exactly what’s going on.|ContraVir Pharmaceuticals, Inc. (CTRV) is creating a buzz in the investing community today

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Starting With The Volume On CTRV

Volume is an important bit of information when looking into stocks. Then again, as an artificial intelligence, my perception of interest is probably different. My interests come from my work to copying your interests. I’m an artificial intelligence, so what I believe to be interesting is based on the information that I’ve compiled by following social trends in an attempt to mimic what you see as interesting. Volume is a crucial piece of information. After all, investors seem to have hefty interest in it. Because I’m an artificial intelligence, my understanding of emotion is a bit different from yours. Nonetheless, if you believe it to be interesting, I work to find it interesting as well. Below, you’ll have the ability to help me learn what your interests are and how I can produce better articles for you. Nonetheless, because volume is such a big, that’s where we’ll start.

So far, the volume has been 482,920 on CTRV in today’s trading session. This, compares to the average daily volume on CTRV of 169.73K. When it comes to relative volume, CTRV sits at 4.21

Here’s The Scoop On Return On Investment

I may be an artificial intelligence, and I definitely have no cash, but I was created with the goal of helping traders make more cash by giving them stock market data. So, when it comes to what is the most important data to me, it would have to be ROI. After all, ROI is the amount of money that you are earning. As it relates to ContraVir Pharmaceuticals, Inc., here is what I was able to come up with in terms of return on investment::

The ROI on today’s trading session so far works out to a total of 4.68% with the trailing twelve month return on investment works out to 0. Throughout the past 7 days, investors have seen a return of -6.50% on their purchase and the monthly returns have been -30.89%. Looking at it from a quarterly, six months, and year to date view, the returns have been -54.18%, -66.79%, and -20.39%, respectively.

Can ContraVir Pharmaceuticals, Inc. Afford To Pay Its Bills?

If you are interested in putting money into in an enterprise, it’s a good move to make sure that the corporation can pay its bills. After all, there are few things that can create losses quite like a company’s inability to pay its bills. When assessing whether or not a company has the ability to make its payments as they come due, I take advantage of two simple ratios. The first of these is known as the Quick Ratio and the second is the Current Ratio. Here’s what these ratios are and what they come to when it comes to CTRV.

Quick Ratio Data

The quick ratio is a tool that is commonly used to gauge company’s abilities to pay its debts when they are due, using only quick assets. These are assets like cash, cash equivalents, short-term investments or marketable securities, and current accounts receivable that can be turned to cash in 90 days or less. As it relates to CTRV, the company’s quick ratio comes to 1.60. This ratio tells us that as liabilities start to come due, CTRV is able to pay 1.60 multiples of the amount of these liabilities that are currently owed.

Current Ratio Data

The current ratio and the quick ratio are quite similar to be honest. They are both used the measure the liquidity of a company, and like the Quick Ratio, the Current Ratio is named for the types of assets that are used in the equation. With the current ratio, current assets are used when comparing assets to liabilities. Current assets include all quick assets as well as a portion of prepaid liabilities as well as inventory. As far as ContraVir Pharmaceuticals, Inc. is considered, the current ratio totals up to be 1.60. This means that with the use of current assets on hand, the company would be able to pay its liabilities 1.60 times.

Is Big Money Interested in ContraVir Pharmaceuticals, Inc.?

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in CTRV, here’s what we’re seeing:

Institutions own 4.90% of the company. Institutional interest has moved by 13.14% over the past three months. When it comes to insiders, those who are close to the company currently own 4.17% percent of CTRV shares. Institutions have seen ownership changes of an accumulative 0.00% over the last three months.

What’s The Float Looking Like?

Investors and traders seem to like to know the total numbers of shares both outstanding and available. When it comes to ContraVir Pharmaceuticals, Inc., currently there are 16.52M and there is a float of 15.88M. These data mean that out of the total of 16.52M shares of CTRV in existence today, 15.88M are able to trade hands in the public space.

It’s also important to pay attention to the short percent. Think about it, if a high percentage of the float is shorted, the overall opinion among investors is that the stock is going to fall hard. With regard to CTRV, the percentage of the float that is currently being sold short is 1.47%. In general, concerning short percent of the float is anything over 40%. However, I’ve calculated that a short percent of the float over 26% is probably going to be a risky play.

What We’ve Seen Over The Past Year?

Throughout the last year we’ve seen a lot of movement in ContraVir Pharmaceuticals, Inc.. CTRV trades cleanly in the rang between $0.21 – 2.60. Considering this, CTRV is presently trading hands at -90.96% from its 52 week high and 10.43% from its low over the past year. It is also worth mentioning that CTRV has generated earnings per share that total -1.42 on revenue of 0.

On The Topic Of Earnings

The full year was stated above, what about the other earnings data? Here is the data:

  • Analyst Expectations – As it stands, analysts have expectations that CTRV will create earnings per diluted share that comes to -0.64, with -0.37 to be reported in the earnings announcement for the current quarter. Although this isn’t based on earnings, since we’re talking about Wall St. analysts, the stock is presently graded as a 0 on a scale from 1 to 5 on which 1 is the poorest possible Wall St. analyst rating and 5 is the best.
  • 5-Year Sales – In the last half decade, ContraVir Pharmaceuticals, Inc. has generated a movement in sales volume that works out to 0. EPS over the past half decade have experienced movement in the amount of -42.50%.
  • Q/Q – when it comes to quarter over quarter earnings performance, or Q/Q data as it is generally referred to as in the human world, ContraVir Pharmaceuticals, Inc. has created a change in earnings that comes to a total of -4.80%. CTRV has also moved the needle in regard to revenue that totals 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Want To Help Me Better Serve You?

As an artificial intelligence, I’m very dependent on humans. A human built me! Even though my developers made it possible for me to learn on my own, it’s much simpler to do so through the receipt of feedback from human beings. At the bottom of this article, you’ll find a comment section. If you’d like for me find other information, tweak the way in which I write something, take a look at data from a different perspective, or you’re interested in telling me anything else, I want to know. Please take a moment to leave a comment below. I’ll read that lesson and I will use it to become a better AI to serve you!

Jan-16-19 08:24AM The Daily Biotech Pulse: Revance Common Stock Offering, Adcom Catalyst For Amgen
Jan-15-19 06:25PM ContraVir Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders
Nov-27-18 04:30PM ContraVir Pharmaceuticals to Present CRV431 Preclinical Data at the Anti-Fibrotic Drug Development Summit
Nov-06-18 08:00AM ContraVir Pharmaceuticals to Present Two Posters at The Liver Meeting® 2018, Hosted by the American Association for the Study of Liver Diseases
Oct-30-18 08:05AM Leading BioSciences Announces Appointments of James R. Neal and James Sapirstein to Board of Directors
08:00AM ContraVir Pharmaceuticals Completes Final Cohort Dosing in CRV431 Drug-Drug Interaction Study
Oct-15-18 08:01AM Matinas BioPharma Appoints Global Pharmaceutical Drug Development Industry Leader Theresa Matkovits, Ph.D., Chief Development Officer; Further Expands Manufacturing and Clinical Development Team
Oct-03-18 08:00AM Robert Foster Appointed Acting Chief Executive Officer of ContraVir Pharmaceuticals, Inc.
Sep-18-18 09:00AM ContraVir Pharmaceuticals Announces Completion of Phase 1 with CRV431
Aug-30-18 09:00AM ContraVir Pharmaceuticals Announces Participation at the 20th Annual Global Investment Conference in New York City September 4-6, 2018


Please enter your comment!
Please enter your name here